SCHEMBL22200549

SCHEMBL22200549

Cc1cc(-c2nc3cnc(N)nc3n(C(C)C)c2=O)cc(F)c1NSCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.37
ALDH1A1 P00352 13/20 0.37
CYP1A2 P05177 12/20 0.37
HSD17B10 Q99714 12/20 0.37
CASP1 P29466 12/20 0.37
CASP7 P55210 11/20 0.37
USP2 O75604 10/20 0.37
CYP3A4 P08684 9/20 0.37
MEN1 O00255 8/20 0.37
KMT2A Q03164 8/20 0.37
CYP2C9 P11712 7/20 0.37
HIF1A Q16665 6/20 0.37
CYP2C19 P33261 5/20 0.37
LMNA P02545 3/20 0.37
CYP2D6 P10635 2/20 0.37
RECQL P46063 2/20 0.37
CLK4 Q9HAZ1 1/20 0.37
MAPK1 P28482 5/20 0.36
HPGD P15428 3/20 0.36
HBB P68871 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200635 0.95 ERN1 (0.39) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200826 0.89 ERN1 (0.39) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200788 0.88 USP2 (0.40) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200338 0.87 ERN1 (0.41) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200816 0.86 ERN1 (0.38) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL25034061 0.85 ERN1 (0.44) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200634 0.81 MTOR (0.41) ALDH1A1CYP1A2HSD17B10CASP1CASP7
SCHEMBL25034190 0.81 ERN1 (0.48) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200371 0.81 PIK3CA (0.38) MTOR
SCHEMBL22200799 0.81 RORC (0.34) ERN1MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed